SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
4.110
+0.650 (18.79%)
At close: Jan 12, 2026, 4:00 PM EST
4.270
+0.160 (3.89%)
After-hours: Jan 12, 2026, 7:59 PM EST
SLS Employees
SELLAS Life Sciences Group had 15 employees as of December 31, 2024. The number of employees decreased by 1 or -6.25% compared to the previous year.
Employees
15
Change (1Y)
-1
Growth (1Y)
-6.25%
Revenue / Employee
n/a
Profits / Employee
-$1,729,467
Market Cap
699.86M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15 | -1 | -6.25% |
| Dec 31, 2023 | 16 | -1 | -5.88% |
| Dec 31, 2022 | 17 | 6 | 54.55% |
| Dec 31, 2021 | 11 | 4 | 57.14% |
| Dec 31, 2020 | 7 | 2 | 40.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLS News
- 14 days ago - SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - GlobeNewsWire
- 5 weeks ago - SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 - GlobeNewsWire
- 2 months ago - SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript - Seeking Alpha
- 2 months ago - SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds - GlobeNewsWire
- 5 months ago - Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026 - Seeking Alpha
- 5 months ago - SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification - GlobeNewsWire
- 6 months ago - SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board - GlobeNewsWire
- 7 months ago - SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts - GlobeNewsWire